What is your tolerance for risk if you knew the odds against you?

Editor's note: The private pharma corporation Moderna with direct connections to the Pentagon pays $400 million to the National Institute of Allergy and Infectious Diseases (NIAID) isn't a conflict of interest? The Pentagon dropped $1.74 billion into Moderna's operations. Did the $400 million paid to Moderna come out of this $1.74 billion from the Pentagon? Honestly, if you knew up front the US military was involved in the development of a Covid injection would you take the injection? Would you allow your children to be injected? Would you allow your children to be injected despite the demonstrable risk of myocarditis (inflammation of the heart)?

_________

Source: Fierce Pharma

Moderna pays US government $400M 'catch-up payment' under new COVID-19 vaccine license

By Eric Sagonowsky | February 24, 2023

Going forward, Moderna agreed to pay "low single-digit royalties" on its vaccine, CFO Jamie Mock said Thursday. (Photo by Lane Turner/The Boston Globe via Getty Images))

Not long after Moderna kicked off its COVID-19 vaccine launch, questions started swirling around the origins of the company's mRNA technology and the intellectual property rights to its vaccines. Now, Moderna and the U.S. government are putting one dispute to bed.

In Moderna's earnings release Thursday, the company said it recently paid the National Institute of Allergy and Infectious Diseases (NIAID) a $400 million "catch-up payment" under a new royalty-bearing license agreement between the parties.

The payment is part of a license agreement between Moderna and NIAID inked late last year. With the deal, Moderna is paying the U.S. government to access "certain patent rights concerning stabilizing prefusion coronavirus spike proteins," Moderna Chief Financial Officer Jamie Mock said on a conference call Thursday.

Going forward, Moderna agreed to pay NIAID "low single-digit royalties" on COVID-19 vaccine sales, Mock added.

This agreement does not put Moderna out of the woods on the patent litigation front. Even after this deal, the vaccine maker is fighting with the U.S. National Institutes of Health over the origins of the core technology in the vaccine, The New York Times points out.

Please go to Fierce Pharma to continue reading.
________

Related:

Deep State Pressing CV19 Fear Button for Control – Dr. Sherri Tenpenny